Order Article Reprints

Mohr P, Scherrer E, Assaf C, Bender M, Berking C, Chandwani S, Eigentler T, Grimmelmann I, Gutzmer R, Haferkamp S, et al. Real-World Therapy with Pembrolizumab: Outcomes and Surrogate Endpoints for Predicting Survival in Advanced Melanoma Patients in Germany. Cancers. 2022; 14(7):1804. https://doi.org/10.3390/cancers14071804

Mohr, Peter, Emilie Scherrer, Chalid Assaf, Marc Bender, Carola Berking, Sheenu Chandwani, Thomas Eigentler, Imke Grimmelmann, Ralf Gutzmer, Sebastian Haferkamp, and et al. 2022. "Real-World Therapy with Pembrolizumab: Outcomes and Surrogate Endpoints for Predicting Survival in Advanced Melanoma Patients in Germany" Cancers 14, no. 7: 1804. https://doi.org/10.3390/cancers14071804

Mohr, P., Scherrer, E., Assaf, C., Bender, M., Berking, C., Chandwani, S., Eigentler, T., Grimmelmann, I., Gutzmer, R., Haferkamp, S., Hassel, J. C., Hauschild, A., Herbst, R., Jiang, R., Kähler, K. C., Krepler, C., Kreuter, A., Leiter, U., Loquai, C., ... Weichenthal, M. (2022). Real-World Therapy with Pembrolizumab: Outcomes and Surrogate Endpoints for Predicting Survival in Advanced Melanoma Patients in Germany. Cancers, 14(7), 1804. https://doi.org/10.3390/cancers14071804